Inducing Immune Control of Bacterial Virulence Regulation

金黄色葡萄球菌（SA），包括耐甲氧西林（MRSA），是最常见的 皮肤和软组织感染（SSTI）的常见原因。到目前为止，还没有预防SA感染的疫苗 在人体试验中取得了成功。与此同时，对疫苗的需求继续升级， 这种病原体获得抗生素耐药性。我们的目标是证明类病毒 颗粒（VLP）作为一个创新的平台，以诱导细菌毒力调节的免疫控制。vlp是 设计靶向细菌感染的疫苗的新方法和基于VLP的疫苗的能力 靶向SA毒力调节尚未研究。因此，本提案的目标是测试 假设VLP上SA毒力调节肽的呈递可用于诱导保护性 免疫力重要的是，与其他平台和实验佐剂不同，VLP目前用于FDA- 已批准的疫苗（如目前的HPV疫苗）。因此，如果使用VLP的实验方法 它们在动物模型中取得了成功，因此很容易转化为人体试验。

PROJECT SUMMARY: Staphylococcus aureus (SA), including methicillin-resistant (MRSA), is the most common cause of skin and soft tissue infection (SSTI) in the US. To date, no vaccine to prevent SA infection has succeeded in human trials. Meanwhile, the need for a vaccine continues to escalate as does the ability of this pathogen to acquire antibiotic resistance. Our goal is to demonstrate the effectiveness of virus-like particles (VLPs) as an innovative platform to induce immune control of bacterial virulence regulation. VLPs are a novel approach to the design of vaccines targeting bacterial infection and the ability of VLP-based vaccines targeting SA virulence regulation has not been investigated. Therefore, the goal of this proposal is to test the hypothesis that presentation of SA virulence regulating peptides on VLPs can be used to induce protective immunity. Importantly, unlike other platforms and experimental adjuvants, VLPs are currently used in FDA- approved vaccines (like the current HPV vaccines). Therefore, if experimental approaches using VLPs are successful in animal models, they can potentially translate into human trials fairly readily.